antidepressants class medications used treat major depressive disorder anxiety disorders chronic pain common side effects antidepressants include dry mouth weight gain dizziness headaches sexual emotional increased risk suicidal thinking behavior taken children adolescents young discontinuation syndrome resembles recurrent depression case ssri class may occur stopping intake antidepressant effects may permanent research regarding effectiveness antidepressants depression adults controversial found meanwhile evidence benefit children adolescents even though antidepressant use considerably increased children adolescents study found commonly prescribed antidepressant medications slightly effective placebos shortterm acute treatments adults major depressive research found placebo effect may account drugs observed research effectiveness antidepressants generally done people severe population exhibits much weaker placebo meaning results may extrapolated general population yet diagnosed anxiety antidepressants prescribed treat major depressive disorder mdd anxiety disorders chronic pain addictions antidepressants often used combination one despite longstanding prominence pharmaceutical advertising idea low serotonin levels cause depression supported scientific proponents monoamine hypothesis depression recommend choosing antidepressant impacts prominent symptoms practice example person mdd also anxious irritable would treated selective serotonin reuptake inhibitors ssris norepinephrine reuptake inhibitors person suffering loss energy enjoyment life would take reuptake uk national institute health care excellence nices guidelines indicate antidepressants routinely used initial treatment mild depression unless persons guidelines recommended antidepressant treatment considered guidelines note cases antidepressants used combination psychosocial interventions continued least six months reduce risk relapse ssris typically better tolerated american psychiatric association apa treatment guidelines recommend initial treatment individually tailored based factors including severity symptoms coexisting disorders prior treatment experience persons preference options may include antidepressants psychotherapy electroconvulsive therapy ect transcranial magnetic stimulation tms light therapy apa recommends antidepressant medication initial treatment choice people mild moderate severe major depression given people severe depression unless ect reviews antidepressants generally find benefit adults hand contend studies antidepressant medication confounded several biases lack active placebo means many people placebo arm doubleblind study may deduce getting true treatment thus destroying doubleblindness short follow termination treatment nonsystematic recording adverse effects strict exclusion criteria samples patients studies paid industry selective publication results means small beneficial effects found may statistically among commonly prescribed antidepressants effective welltolerated escitalopram paroxetine sertraline agomelatine children adolescents moderate severe depressive disorder evidence suggests fluoxetine either without cognitive behavioral therapy best treatment research needed sertraline escitalopram duloxetine may also help reduce systematic review metaanalysis randomized controlled trials antidepressants major depressive disorder found medications provided small doubtful benefits terms quality likewise systematic review metaanalysis randomized controlled trials antidepressants major depressive disorder children adolescents found small improvements quality quality life outcome measure often selectively reported trials children adolescents fluvoxamine effective treating range anxiety fluoxetine sertraline paroxetine also help managing various forms anxiety children metaanalyses published unpublished trials found antidepressants placebosubtracted effect size standardized mean difference smd treatment anxiety disorders around equates small improvement roughly magnitude benefit effectiveness treatment effect size smd improvement placebo trials antidepressants anxiety disorders approximately large improvement terms effect size relation benefit antidepressants anxiety disorders attributable placebo responses rather effects antidepressants antidepressants recommended national institute health care excellence nice treatment generalized anxiety disorder gad failed respond conservative measures education selfhelp activities gad common disorder central feature excessively worrying numerous events key symptoms include excessive anxiety events issues going around difficulty controlling worrisome thoughts persists least months antidepressants provide modest moderate reduction anxiety efficacy different antidepressants antidepressants used treatment social anxiety disorder efficacy entirely convincing small proportion antidepressants showed effectiveness condition paroxetine first drug fdaapproved disorder efficacy considered beneficial although everyone responds favorably drug sertraline fluvoxamine extendedrelease later approved well escitalopram used offlabel acceptable efficiency however enough evidence support citalopram treating social anxiety disorder fluoxetine better placebo clinical trials ssris used firstline treatment social anxiety work everyone one alternative would venlafaxine snri shown benefits social phobia five clinical trials placebo snris considered particularly useful disorder many undergo testing unclear duloxetine desvenlafaxine provide benefits people social anxiety however another class antidepressants called maois considered effective social anxiety come many unwanted side effects rarely used phenelzine shown good treatment option use limited dietary restrictions moclobemide rima showed mixed results still received approval european countries social anxiety disorder tca antidepressants clomipramine imipramine considered effective anxiety disorder particular leaves ssris paroxetine sertraline fluvoxamine cr acceptable tolerated treatment options ssris secondline treatment adult disorder ocd mild functional impairment firstline treatment moderate severe children ssris considered secondline therapy moderatetosevere impairment close monitoring psychiatric adverse sertraline fluoxetine effective treating ocd children clomipramine tca drug considered effective useful ocd however used secondline treatment less welltolerated ssris despite shown superiority fluvoxamine trials ssris used effectively ocd snri use may also attempted though snris approved treatment ocd despite treatment options many patients remain symptomatic initiating medication less half achieve placebo responses large component benefit antidepressants treatment depression however placebo responses antidepressants lower magnitude treatment ocd compared depression metaanalysis found placebo improvement effect sizes smd depression anxiety disorders ocd antidepressants one treatment options ptsd however efficacy well established paroxetine sertraline fda approved treatment ptsd paroxetine slightly higher response remission rates sertraline condition however neither drug considered helpful broad patient demographic fluoxetine venlafaxine used offlabel fluoxetine produced unsatisfactory mixed results venlafaxine showed response rates significantly higher paroxetine sertraline achieved however address many symptoms ptsd paroxetine sertraline part due fact venlafaxine snri class drugs inhibits reuptake norepinephrine may cause anxiety patients fluvoxamine escitalopram citalopram welltested disorder maois may helpful used much unwanted side effects leaves paroxetine sertraline acceptable treatment options people although effective antidepressants panic disorder treated relatively well medications compared disorders several classes antidepressants shown efficacy disorder ssris snris used firstline paroxetine sertraline fluoxetine fdaapproved panic disorder fluvoxamine escitalopram citalopram also considered effective snri venlafaxine also approved condition unlike social anxiety ptsd tcas antidepressants like clomipramine imipramine shown efficacy panic disorder moreover maoi phenelzine also considered useful panic disorder many drugs treatment however starting dose must lower one used major depressive disorder people reported increase anxiety result starting medication conclusion panic disorders treatment options seem acceptable useful condition many people still symptomatic treatment residual antidepressants recommended alternative additional first step selfhelp programs treatment bulimia ssris fluoxetine particular preferred antidepressants due acceptability tolerability superior reduction symptoms shortterm trials longterm efficacy remains poorly characterized bupropion recommended treatment eating disorders due increased risk similar recommendations apply binge eating ssris provide shortterm reductions binge eating behavior associated significant weight clinical trials generated mostly negative results use ssris treatment anorexia treatment guidelines national institute health care excellence recommend use ssris disorder american psychiatric association apa note ssris confer advantage regarding weight gain may used treatment coexisting depressive anxiety metaanalysis concluded antidepressant treatment favorably affects pain healthrelated quality life depression sleep fibromyalgia syndrome tricyclics appear effective class moderate effects pain sleep small effects fatigue healthrelated quality life fraction people experiencing pain reduction tricyclics versus placebo ssris snris fractions people experiencing pain reduction placebo comparator arms corresponding placebo comparator arms respectively discontinuation treatment due side effects antidepressants including amitriptyline fluoxetine duloxetine milnacipran moclobemide pirlindole recommended european league rheumatism eular treatment fibromyalgia based limited metaanalysis cochrane collaboration found antidepressant duloxetine effective treatment pain resulting diabetic group reviewed data amitriptyline treatment neuropathic pain found limited useful randomized clinical trial data concluded long history successful use community treatment fibromyalgia neuropathic pain justified continued group concerned potential overestimation amount pain relief provided amitriptyline highlighted small number people experience significant pain relief taking antidepressants may modestly helpful treating people depression alcohol dependence however evidence supporting association low bupropion used help people stop smoking antidepressants also used control symptoms antidepressants may used relieve pain people active rheumatoid arthritis however research antidepressants shown superior placebo treating depression individuals physical illness although reporting bias may exaggerated among individuals treated given antidepressant show approximately onethird people achieve full remission onethird experience response onethird nonresponders partial remission characterized presence poorly defined residual symptoms symptoms typically include depressed mood anxiety sleep disturbance fatigue diminished interest pleasure currently unclear factors predict partial remission however clear residual symptoms powerful predictors relapse relapse rates three six times higher people residual symptoms experience full addition antidepressant drugs tend lose efficacy throughout longterm maintenance according data centers disease control prevention less onethird americans taking one antidepressant medication seen mental health professional previous several strategies used clinical practice try overcome limits include switching medication augmentation combination controversy amongst researchers regarding efficacy riskbenefit ratio although antidepressants consistently outperform placebo metaanalyses difference modest clear statistical superiority results clinical aggregate effect antidepressants typically results changes threshold clinical significance depression rating proponents antidepressants counter common scale hdrs suitable assessing drug action threshold clinical significance arbitrary antidepressants consistently result significantly raised scores mood item assessments antidepressants using alternative sensitive scales madrs result marked difference hdrs likewise find marginal clinical another hypothesis proposed explain poor performance antidepressants clinical trials high treatment response heterogeneity patients differ strongly response antidepressants could influence average response heterogeneity could obscured averaging studies supported hypothesis difficult measure treatment effect poor complex clinical trial design might also account small effects seen randomized controlled trials used approve drugs short may capture full effect additionally placebo effect might inflated trials frequent clinical consultation lowering comparative performance critics agree current clinical trials poorlydesigned limits knowledge naturalistic studies stard produced results suggest antidepressants may less effective clinical practice randomized controlled critics antidepressants maintain superiority antidepressants placebo result systemic flaws clinical trials research trials conducted industry involvement tend produce favorable results accordingly many trials included metaanalyses high risk additionally metaanalyses coauthored industry employees find favorable results results antidepressant trials significantly likely published favorable unfavorable results often left unpublished misreported phenomenon called publication bias selective although issue diminished time remains obstacle accurately assessing efficacy misreporting clinical trial outcomes serious adverse events suicide ghostwriting antidepressant trials widespread practice prominent researchers socalled key opinion leaders attach names studies actually written pharmaceutical company employees particular concern psychoactive effects antidepressants may lead unblinding participants researchers enhancing placebo effect biasing therefore maintained antidepressants may active flaws research literature taken account metaanalyses may find inflated results basis poor critics contend antidepressants proven sufficiently effective rcts clinical practice widespread use antidepressants also note adverse effects including withdrawal difficulties likely underreported skewing clinicians ability make riskbenefit accordingly believe antidepressants overused particularly nonsevere depression conditions critics charge widespread use public acceptance antidepressants result pharmaceutical advertising research manipulation current mainstream psychiatric opinion recognizes limitations antidepressants recommends use adults severe depression firstline american psychiatric association practice guideline advises response achieved within following six eight weeks treatment antidepressant switch antidepressant class different class metaanalysis review found wide variation findings prior studies people failed respond ssri antidepressant showed response new drug however antidepressants individual previously tried less likely benefit new antidepressant however later metaanalysis found difference switching new drug staying old medication although treatmentresistant people responded switched new drug responded without partial response american psychiatric association apa guidelines suggest augmentation adding drug different class include lithium thyroid augmentation dopamine agonists sex steroids nris glucocorticoidspecific agents newer combination strategy involves adding another antidepressant usually different class affect mechanisms although may used clinical practice little evidence relative efficacy adverse effects tests conducted include use psychostimulants augmentation therapy several studies shown efficacy combining modafinil treatmentresistant people used help combat ssriassociated effects antidepressants typically continue course medication ends results high rate relapse metaanalysis found people responded antidepressant relapsed still taking compared whose antidepressant switched gradual loss therapeutic benefit occurs minority people course strategy involving use pharmacotherapy treatment acute episode followed psychotherapy residual phase suggested patients wish stop antidepressants engaging brief psychological interventions preventive cognitive mindfulnessbased cognitive therapy tapering found diminish risk antidepressants cause various adverse effects depending individual drug almost medication involved serotonin regulation potential cause serotonin toxicity also known serotonin syndrome excess serotonin induce mania restlessness agitation emotional lability insomnia confusion primary although condition serious particularly common generally appearing high doses medications assuming proper medical intervention taken within hours rarely antidepressants appear increase risk diabetes maois tend pronounced sometimes fatal interactions wide variety medications overthecounter drugs taken foods contain high levels tyramine eg mature cheese cured meats yeast extracts may cause potentially lethal hypertensive crisis lower doses person may experience headache due increase blood response adverse effects different type maoi class reversible inhibitor monoamine oxidase rima developed primary advantage rimas require person follow special diet purportedly effective ssris tricyclics treating depressive tricyclics ssri cause socalled druginduced qt prolongation especially older condition degenerate specific type abnormal heart rhythm called torsades de points potentially lead sudden cardiac antidepressants also believed increase thoughts suicidal ideation antidepressants associated increased risk dementia older ssri use pregnancy associated variety risks varying degrees proof causation depression independently associated negative pregnancy outcomes determining extent observed associations antidepressant use specific adverse outcomes reflect causative relationship difficult cases attribution adverse outcomes antidepressant exposure seems fairly clear ssri use pregnancy associated increased risk spontaneous abortion associated preterm birth low birth systematic review risk major birth defects antidepressantexposed pregnancies found small increase risk major malformations risk cardiovascular birth defects differ nonexposed study fluoxetineexposed pregnancies found increase risk major malformations reach statistical studies found increased risk cardiovascular birth defects among depressed mothers undergoing ssri treatment suggesting possibility ascertainment bias eg worried mothers may pursue aggressive testing another study found increase cardiovascular birth defects increased risk major malformations ssri exposed fda advises risk birth defects use maoi avoided systematic review metaanalysis found antidepressant use pregnancy statistically significantly associated pregnancy outcomes gestational age preterm birth outcomes review cautioned differences exposed unexposed groups small doubtful whether clinically neonate infant less days old may experience withdrawal syndrome abrupt discontinuation antidepressant birth antidepressants present varying amounts breast milk effects infants currently moreover ssris inhibit nitric oxide synthesis plays important role setting vascular tone several studies pointed increased risk prematurity associated ssri use association may due increased risk preeclampsia another possible problem antidepressants chance antidepressantinduced mania hypomania people without diagnosis bipolar disorder many cases bipolar depression similar unipolar depression therefore person misdiagnosed unipolar depression given antidepressants studies shown antidepressantinduced mania occur people bipolar bipolar depression antidepressants frequently ssris exacerbate trigger symptoms hypomania bupropion associated lower risk mood switch studies shown use antidepressants correlated increased risk suicidal behavior thinking suicidality aged years problem serious enough warrant government intervention us food drug administration fda warn increased risk suicidality antidepressant according fda heightened risk suicidality occurs within first one two months national institute health care excellence nice places excess risk early stages metaanalysis suggests relationship antidepressant use suicidal behavior thoughts compared placebo use antidepressants associated increase suicidal behavior thoughts among years old younger review rcts epidemiological studies healy whitaker found increase suicidal acts factor effect possibly mild protective effect among aged antidepressant treatment protective effect suicidality among aged sexual side effects also common ssris loss sexual drive failure reach orgasm erectile although usually reversible sexual sideeffects rare cases continue drug completely study outpatients overall sexual dysfunction antidepressants averaged ssri values mirtazapine nefazodone amineptine moclobemide moclobemide selective reversible maoa inhibitor cause sexual lead improvement aspects sexual biochemical mechanisms suggested causative include increased serotonin particularly affecting receptors decreased dopamine decreased norepinephrine blockade cholinergic receptors inhibition nitric oxide synthetase elevation prolactin mirtazapine reported fewer sexual side effects likely antagonizes receptors may cases reverse sexual dysfunction induced ssris bupropion weak ndri nicotinic antagonist may useful treating reduced libido result ssri certain antidepressants may cause emotional blunting characterized reduced intensity positive negative emotions well symptoms apathy indifference may experienced either beneficial detrimental depending side effect particularly associated serotonergic antidepressants like ssris snris may less atypical antidepressants like bupropion agomelatine higher doses antidepressants seem likely produce emotional blunting lower emotional blunting decreased reducing dosage discontinuing medication switching different antidepressant may less propensity causing side changes appetite weight common among antidepressants largely drugdependent related neurotransmitters affect mirtazapine paroxetine example may associated weight gain andor increased others bupropion venlafaxine achieve opposite antihistaminic properties certain tca tecaclass antidepressants shown contribute common side effects increased appetite weight gain associated classes medication nationwide cohort study south korea observed link ssri use bone loss particularly recent users study also stressed need research better understand review found ssris along tricyclic antidepressants associated significant increase risk osteoporotic fractures peaking months initiation moving back towards baseline year treatment stopped effects exhibited relationship within ssris varied different drugs metaanalysis small studies found reduction bone density lumbar spine ssri users affected older people metaanalysis found antidepressants associated significantly increased risk death new cardiovascular complications general conversely risks greater people existing cardiovascular antidepressant discontinuation syndrome also called antidepressant withdrawal syndrome condition occur following interruption reduction discontinuation antidepressant symptoms may include flulike symptoms trouble sleeping nausea poor balance sensory changes problem usually begins within three days may last several rarely psychosis may discontinuation syndrome occur stopping antidepressant including selective serotonin reuptake inhibitors ssris reuptake inhibitors snris tricyclic antidepressants risk greater among taken medication longer medication question short underlying reason occurrence diagnosis based methods prevention include gradually decreasing dose among wish stop though possible symptoms occur treatment may include restarting medication slowly decreasing people may also switched longacting antidepressant fluoxetine gradually approximately people suddenly stop antidepressant develop antidepressant discontinuation condition generally though half people symptoms describe restart antidepressants due severity antidepressants act via large number different mechanisms includes serotonin reuptake inhibition ssris snris tcas vilazodone vortioxetine norepinephrine reuptake inhibition nris snris tcas dopamine reuptake inhibition bupropion amineptine nomifensine direct modulation monoamine receptors vilazodone vortioxetine saris agomelatine tcas tecas antipsychotics monoamine oxidase inhibition maois nmda receptor antagonism ketamine esketamine dextromethorphan among others eg brexanolone antidepressants also additional actions like sigma receptor modulation certain ssris tcas dextromethorphan antagonism histamine muscarinic acetylcholine receptors tcas earliest widely known scientific theory antidepressant action monoamine hypothesis traced back theory states depression due imbalance often deficiency monoamine neurotransmitters namely serotonin norepinephrine andor however serotonin particular implicated serotonin hypothesis monoamine hypothesis originally proposed based observations reserpine drug depletes monoamine neurotransmitters produced depressive effects certain hydrazine antituberculosis agents like iproniazid prevent breakdown monoamine neurotransmitters produced apparent antidepressant currently marketed antidepressants monoaminergic actions theoretically consistent monoamine despite widespread nature monoamine hypothesis number limitations one monoaminergic antidepressants delayed onset action least week secondly many people depression respond monoaminergic number alternative hypotheses proposed including hypotheses involving glutamate neurogenesis epigenetics cortisol hypersecretion inflammation among major systematic umbrella review joanna moncrieff colleagues showed serotonin theory depression supported evidence wide variety authors concluded association serotonin depression evidence strongly supports theory depression caused low serotonin activity literature described lack support theory many expert responses review stated monoamine hypothesis already long abandoned spite general public western countries believing theory true many field psychiatry continuing promote theory recent addition serotonin umbrella review reviews found reserpine drug depletes monoamine serotonin norepinephrine consistent evidence producing depressive instead findings reserpine mood highly mixed similar proportions studies finding influence mood produces depressive effects actually antidepressant relation general monoamine hypothesis opposed serotonin theory depression likewise appear wellsupported serotonin monoamine hypotheses depression heavily promoted pharmaceutical industry eg advertisements psychiatric profession large despite lack evidence support case pharmaceutical industry attributed obvious financial incentives theory creating bias nonpharmacological treatments alternative theory antidepressant action proposed certain academics irving kirsch joanna moncrieff work largely entirely via placebo supported metaanalyses randomized controlled trials antidepressants depression consistently show placebo groups trials improve much antidepressant groups antidepressants marginally effective depression difference antidepressants placebo corresponds effect size smd turn equates additional improvement hrsd madrs depression rating scales used differences effectiveness different antidepressants small clinically small advantage antidepressants placebo often statistically significant basis regulatory approval sufficiently modest clinical significance moreover small advantage antidepressants placebo may simply methodological artifact caused unblinding due psychoactive effects side effects antidepressants turn resulting enhanced placebo effects apparent antidepressant placebos found modify activity several brain regions increase levels dopamine endogenous opioids reward argued kirsch although antidepressants may used efficaciously depression active placebos limited significant pharmacological side effects risks therefore nonpharmacological therapies psychotherapy lifestyle changes similar efficacy antidepressants adverse effects ought preferred treatments people placebo response improvement scores placebo group clinical trials due placebo effect also due phenomena spontaneous remission regression depression tends episodic course people eventually recovering even medical intervention people tend seek treatment well enroll clinical trials feeling metaanalyses trials depression therapies kirsch estimated based improvement untreated waitinglist controls spontaneous remission regression mean account improvement depression scores antidepressant however another academic michael p hengartner argued presented evidence spontaneous remission regression mean might actually account improvement depression scores antidepressants substantial placebo effect observed clinical trials might largely methodological suggests antidepressants may associated much less genuine treatment benefit whether due placebo effect antidepressant traditionally selective serotonin reuptake inhibitors ssris believed increase extracellular level neurotransmitter serotonin limiting reabsorption presynaptic cell increasing level serotonin synaptic cleft available bind postsynaptic receptor varying degrees selectivity monoamine transporters pure ssris weak affinity norepinephrine dopamine transporters ssris widely prescribed antidepressants many efficacy ssris mild moderate cases depression reuptake inhibitors snris potent inhibitors reuptake serotonin norepinephrine neurotransmitters known play important role mood snris contrasted widely used selective serotonin reuptake inhibitors ssris act mostly upon serotonin alone human serotonin transporter sert norepinephrine transporter net membrane proteins responsible reuptake serotonin norepinephrine balanced dual inhibition monoamine reuptake may offer advantages antidepressants drugs treating wider range snris sometimes also used treat anxiety disorders disorder ocd attention deficit hyperactivity disorder adhd chronic neuropathic pain fibromyalgia syndrome fms relief menopausal symptoms serotonin modulator stimulators smss sometimes referred simply serotonin modulators type drug multimodal action specific serotonin neurotransmitter system precise smss simultaneously modulate one serotonin receptors inhibit reuptake serotonin term coined reference mechanism action serotonergic antidepressant vortioxetine acts serotonin reuptake inhibitor sri partial agonist receptor antagonist however also technically applied vilazodone antidepressant well acts sri receptor partial alternative term serotonin partial agonistreuptake inhibitor spari applied serotonin antagonist reuptake inhibitors saris mainly used antidepressants also anxiolytics hypnotics act antagonizing serotonin receptors inhibiting reuptake serotonin norepinephrine andor dopamine additionally also act receptor antagonists majority currently marketed saris belong phenylpiperazine class compounds include trazodone nefazodone majority tricyclic antidepressants tcas act primarily reuptake inhibitors snris blocking serotonin transporter sert norepinephrine transporter net respectively results elevation synaptic concentrations neurotransmitters therefore enhancement notably sole exception amineptine tcas weak affinity dopamine transporter dat therefore low efficacy dopamine reuptake inhibitors although tcas sometimes prescribed depressive disorders largely replaced clinical use parts world newer antidepressants selective serotonin reuptake inhibitors ssris reuptake inhibitors snris norepinephrine reuptake inhibitors nris adverse effects found similar level tcas tetracyclic antidepressants tecas class antidepressants first introduced named chemical structure contains four rings atoms closely related tricyclic antidepressants tcas contain three rings atoms monoamine oxidase inhibitors maois chemicals inhibit activity monoamine oxidase enzyme family long history use medications prescribed treatment depression particularly effective treating atypical also used treatment parkinsons disease several disorders potentially lethal dietary drug interactions maois historically reserved last line treatment used classes antidepressant drugs example selective serotonin reuptake inhibitors tricyclic antidepressants maois found effective treatment panic disorder social atypical mixed anxiety depression posttraumatic stress well borderline personality maois appear particularly effective management bipolar depression according reports maoi efficacy disorder ocd trichotillomania dysmorphophobia avoidant personality disorder reports uncontrolled case maois also used treatment parkinsons disease targeting maob particular therefore affecting dopaminergic neurons well providing alternative migraine prophylaxis inhibition maoa maob used treatment clinical depression anxiety disorders nmda receptor antagonists like ketamine esketamine rapidacting antidepressants seem work via blockade ionotropic glutamate nmda nmda antagonists may also play role treating depression combination medication dextromethorphanbupropion auvelity contains nmda receptor antagonist dextromethorphan approved united states treating major depressive see list antidepressants management depression drugs specifically characterized adjunct medications umbrella category substances increase potency enhance work affecting variables close antidepressant sometimes affecting completely different mechanism action may attempted depression treatments successful past common types adjunct medication techniques generally fall following categories unknown undergoing psychological therapy time taking antidepressants enhances antidepressive effect lithium used augment antidepressant therapy failed respond antidepressants furthermore lithium dramatically decreases suicide risk recurrent evidence addition thyroid hormone triiodothyronine patients normal thyroid psychopharmacologists also tried adding stimulant particular however use stimulants cases treatmentresistant depression relatively review article published found psychostimulants may effective treatmentresistant depression concomitant antidepressant therapy certain conclusion could drawn due substantial deficiencies studies available consideration somewhat contradictory nature idea antidepressant least melancholy thought synonymous depression least since publication pamphlet pil purge melancholie preprative pvrgation topping copping capping take either whether mash squash dash diddle come derrie come daw together thomas durfeys wit mirth pills purge melancholy title large collection songs published opioids amphetamines commonly used use later restricted due addictive nature side extracts herb st johns wort used nerve tonic alleviate st johns wort fell favor countries centuries except germany hypericum extracts eventually licensed packaged prescribed smallscale efficacy trials carried attention grew following remains overthecounter drug otc supplement countries lead contamination associated usage seen concerning lead levels women united states taking st johns wort elevated research continues investigate active component hyperforin understand mode irving selikoff edward h robitzek working sea view hospital staten island began clinical trials two new antituberculosis agents developed hoffmanlaroche isoniazid iproniazid patients poor prognosis initially treated nevertheless condition improved dramatically selikoff robitzek noted subtle general stimulation patients exhibited renewed vigor indeed occasionally served introduce disciplinary promise cure tuberculosis sea view hospital trials excitedly discussed mainstream press learning stimulating side effects isoniazid cincinnati psychiatrist max lurie tried patients following year harry salzer reported isoniazid improved depression twothirds patients coined term antidepressant refer similar incident took place paris jean delay head psychiatry sainteanne hospital heard effect pulmonology colleagues cochin hospital lurie salzer delay resident jeanfrancois buisson reported positive effect isoniazid depressed mode antidepressant action isoniazid still unclear speculated effect due inhibition diamine oxidase coupled weak inhibition monoamine oxidase selikoff robitzek also experimented another antituberculosis drug iproniazid showed greater psychostimulant effect pronounced later jackson smith gordon kamman george e crane frank ayd described psychiatric applications iproniazid ernst zeller found iproniazid potent monoamine oxidase nevertheless iproniazid remained relatively obscure nathan kline influential head research rockland state hospital began popularize medical popular press psychic roche put significant marketing effort behind sales grew recalled due reports lethal antidepressant effect tricyclic threeringed compound first discovered roland kuhn swiss psychiatric hospital antihistamine derivatives used treat surgical shock later neuroleptics although reserpine shown effective placebo alleviating anxious depression neuroleptics developed sedatives antipsychoticsmedical citation needed attempting improve effectiveness chlorpromazine kuhn conjunction geigy pharmaceutical company discovered compound g later renamed imipramine imipramine beneficial effect patients depression showed mental motor retardation kuhn described new compound thymoleptic taking hold emotions contrast neuroleptics taking hold nerves gradually became established resulting patent manufacture us häfliger antidepressants became prescription drugs estimated fifty one hundred individuals per million kind depression new drugs would treat pharmaceutical companies enthusiastic marketing small market sales remained poor compared sales medical source marketed different imipramine remained common use numerous successors introduced use monoamine oxidase inhibitors maoi increased development introduction reversible forms affecting maoa subtype inhibitors making drug safer thought mode action tricyclics inhibit norepinephrine reuptake however norepinephrine reuptake became associated stimulating effects later tricyclics thought affect serotonin proposed carlsson lindqvist well lapin oxenkrugmedical citation needed researchers began process rational drug design isolate antihistaminederived compounds would selectively target systems first compound patented zimelidine first released clinically indalpine fluoxetine approved commercial use us food drug administration fda becoming first blockbuster ssri fluoxetine developed eli lilly company early bryan molloy klaus schmiegel david wong ssris became known novel antidepressants along newer drugs snris nris various selective esketamine brand name spravato first rapidacting antidepressant approved clinical treatment depression introduced indication march united randomized controlled trial evaluated rapid antidepressant effects psychedelic ayahuasca treatmentresistant depression positive fda granted breakthrough therapy designation psilocybinassisted therapy treatmentresistant depression fda granted breakthrough therapy designation psilocybin therapy treating major depressive systematic review published lancet comparing efficacy different first second generation antidepressants found antidepressant drugs tended perform better cause less adverse events novel experimental treatments compared evaluated years unpublished data also associated smaller positive effect sizes however review find evidence bias associated industry funded research uk figures reported indicated number antidepressants prescribed national health service nhs almost doubled analysis published showed number antidepressants dispensed annually community went million years rising million million nearly rise occurred four years banking crash time annual increase prescriptions rose sources also suggest aside recession factors may influence changes prescribing rates may include improvements diagnosis reduction stigma surrounding mental health broader prescribing trends gp characteristics geographical location housing status another factor may contribute increasing consumption antidepressants fact medications used conditions including social anxiety posttraumatic stress disorder number adolescents years england prescribed antidepressants doubled hand antidepressant prescriptions children aged england decreased april prescriptions increased age groups people aged peaked first covid lockdown march according national institute health care excellence nice guidelines antidepressants children adolescents depression obsessivecompulsive disorder ocd prescribed together therapy assessed child adolescent psychiatrist however yearolds prescribed ssri gp seen specialist psychiatrist seen pediatrician half prescriptions depression anxiety latter licensed treatment among suggested possible reasons gps following guidelines difficulties accessing talking therapies long waiting lists urgency according researchers strict adherence treatment guidelines would limit access effective medication young people mental health united states antidepressants commonly prescribed medication estimated million long term months users roughly percent white people united states took antidepressants compared black people united united states commonly prescribed antidepressants us retail market netherlands netherlands paroxetine prescribed antidepressant followed amitriptyline citalopram worldwide people follow practitioners instructions taking us appeared around people take antidepressants directed people fail take antidepressants greater risk drug help symptoms get worse miss work less productive work person may academicswho highlighted need examine use antidepressants medical treatments crosscultural terms various cultures prescribe observe different manifestations symptoms meanings associations depression medical conditions within crosscultural discrepancies argued implications perceived efficacy use antidepressants strategies treatment depression different india antidepressants largely seen tools combat marginality promising individual ability reintegrate society view association observed antidepressants function inhibiting reuptake neurotransmitters serotonin dopamine drugs interfere natural neurotransmitter levels organisms impacted indirect antidepressants fluoxetine sertraline detected aquatic organisms residing effluentdominated presence antidepressants surface waters aquatic organisms caused concern ecotoxicological effects aquatic organisms due fluoxetine exposure coral reef fish demonstrated modulate aggressive behavior artificially increasing serotonin levels crustaceans temporarily reverse social status turn subordinates aggressive territorial dominant exposure fluoxetine demonstrated increase serotonergic activity fish subsequently reducing aggressive perinatal exposure fluoxetine relevant environmental concentrations shown lead significant modifications memory processing impairment may disadvantage cuttlefish decrease survival somewhat less orally administered fluoxetine excreted humans unchanged httpsenwikipediaorgwikiantidepressant